We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Siemens and Nephromics to Develop Preeclampsia Diagnostic Assays

By LabMedica International staff writers
Posted on 07 Sep 2011
Print article
Siemens Healthcare Diagnostics (Tarrytown, NY, USA) has entered into a licensing agreement with Nephromics, LLC (Chestnut Hill, MA, USA) to develop two assays to be used as an aid in the diagnosis of preeclampsia.

The assays being developed are for the detection of two biomarkers, soluble fms-like tyrosine-kinase-1 (SFLT-1) and placental growth factor (PLGF). Clinical studies have shown that these two assays, when used in conjunction with each other, are better predictors of preeclampsia than either marker alone. Under the terms of the agreement, Siemens Healthcare Diagnostics will obtain rights for the development of the SFLT-1 and PLFG assays.

The addition of these assays will complement Siemens’ existing portfolio of integrated OB/GYN diagnostic solutions, which include both ultrasound imaging and reproductive endocrinology laboratory testing. Healthcare professionals are looking to the integration of in vitro and in vivo diagnostics in the practice of maternal/fetal diagnostic medicine.

Preeclampsia affects at least 5% to 8% of all pregnancies and is a leading cause of  maternal and fetal mortality. Currently, the standard methodologies for prescreening pregnant women at risk for preeclampsia are routine blood pressure monitoring and testing for protein in the urine during prenatal visits. However, with these methods, preeclampsia is often diagnosed at an advanced stage when there are limited treatment options.

“Given the prevalence and associated mortality with preeclampsia, clinicians need better diagnostic tools to identify the condition before it becomes advanced,” said Dave Hickey, CEO, Chemistry, Immunoassay, Automation, and Diagnostics IT Business Unit, Siemens Healthcare Diagnostics. “The development of assays designed to detect preeclampsia earlier is an evolving area of diagnostic medicine, and we are excited to enter into the agreement with Nephromics to offer these diagnostic solutions to our customers, clinicians, and patients.”

Related Links:

Siemens Healthcare Diagnostics






New
Gold Member
Syphilis Screening Test
VDRL Antigen MR
Automated Blood Typing System
IH-500 NEXT
New
Toxoplasma Gondii Test
Toxo IgG ELISA Kit
New
Hepatitis B Virus Test
HBs Ab – ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.